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Ataxia, dystonia and myoclonus in adult
patients with Niemann-Pick type C
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F. J. van Spronsen4, J. M. Spikman2,5, T. J. de Koning4,6 and M. A. J. Tijssen1*
Abstract
Background: Niemann-Pick type C (NP-C) is a rare autosomal recessive progressive neurodegenerative disorder
caused by mutations in the NP-C 1 or 2 gene. Besides visceral symptoms, presentation in adolescent and adult
onset variants is often with neurological symptoms. The most frequently reported presenting symptoms of NP-C in
adulthood are psychiatric symptoms (38 %), cognitive decline (23 %) and ataxia (20 %). Myoclonus can be present,
but its value in early diagnosis and the evolving clinical phenotype in NP-C is unclear. In this paper we present
eight Dutch cases of NP-C of whom five with myoclonus.
Methods: Eight patients with genetically confirmed NP-C were recruited from two Dutch University Medical
Centers. A structured interview and neuropsychological tests (for working and verbal memory, attention and
emotion recognition) were performed. Movement disorders were assessed using a standardized video protocol.
Quality of life was evaluated by questionnaires (Rand-36, SIP-68, HAQ). In four of the five patients with myoclonic
jerks simultaneous EEG with EMG was performed.
Results: A movement disorder was the initial neurological symptom in six patients: three with myoclonus and
three with ataxia. Two others presented with psychosis. Four experienced cognitive deficits early in the course of
the disease. Patients showed cognitive deficits in all investigated domains. Five patients showed myoclonic jerks,
including negative myoclonus. In all registered patients EEG-EMG coherence analysis and/or back-averaging proved
a cortical origin of myoclonus. Patients with more severe movement disorders experienced significantly more
physical disabilities.
Conclusions: Presenting neurological symptoms of NP-C include movement disorders, psychosis and cognitive
deficits. At current neurological examination movement disorders were seen in all patients. The incidence of
myoclonus in our cohort was considerably higher (63 %) than in previous publications and it was the presenting
symptom in 38 %. A cortical origin of myoclonus was demonstrated. Our data suggest that myoclonus may be
overlooked in patients with NP-C. All patients scored significantly lower on physical domains of HRQoL.
Symptomatic treatment of movement disorders may improve physical functioning and subsequently HRQoL.
Keywords: Niemann-Pick type C, Cortical myoclonus, EEG-EMG coherence, Ataxia, Cognitive deficits
Abbreviations: EEG- EMG, Electroencephalography- electromyography; GCI, Global Clinical Impressions Scale;
HRQol, Health related quality of life; NP-C, Niemann-Pick type C; VSGP, Vertical supranuclear gaze palsy
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Background
Niemann-Pick type C (NP-C) is a rare autosomal reces-
sive neurodegenerative disorder with an estimated inci-
dence of 1 per 120.000 live births [1]. The disorder is
caused by mutations in the NP-C 1 (95 %) or NP-C 2
gene (5 %). Although the exact cellular functions of the
proteins remain to be elucidated, they are involved in
cellular lipid transport/trafficking and mutated proteins
lead to (lysosomal) accumulation of lipids. Lipid storage
products accumulate in many organs including the
brain, resulting in cerebral degeneration with progressive
neurological symptoms, cognitive decline and psychiatric
symptoms. NP-C is a very heterogeneous disorder with
regard to age of onset and clinical presentation. The age
of onset can vary from the newborn period to adulthood.
The neonatal variant usually presents with liver disease
at or soon after birth and causes early death. After the
newborn period, early- and late- infantile NP-C (0–6
years), juvenile NP-C (6–15 years) and adolescent/adult
NP-C (>15 years) can occur and patients mainly present
with neurological symptoms, although visceral symp-
toms, in particular in children also occur [2, 3].
The neurological symptoms in the adolescent or adult-
hood form of NP-C start insidiously and have a slower
progression compared to children [2]. The adult onset
forms of NP-C were considered rare, but recent studies
suggest that NP-C in adulthood is under-recognized
[2–4]. Long delays between the onset of neurological
manifestations and genetic conformation of NP-C are
not uncommon, [3] likely because of the more insidious
course and nonspecific presenting symptoms. The most
frequently reported presenting symptoms of NP-C in
adulthood are psychiatric symptoms (38 %), cognitive de-
cline (23 %), ataxia (20 %) and other movement disorders
including dystonia (11 %) [4, 5]. Especially the combin-
ation of neurological, visceral and psychiatric symptoms
is considered to be highly suggestive for the diagnosis
NP-C [6]. As treatment options for NP-C have become
available, early identification of NP-C is important to
prevent further deterioration and progress of neuro-
logical manifestations [7].
The frequency of myoclonus in NP-C was found around
8, 5 % in a retrospective review, [8] but the frequency of
myoclonus being a presenting symptom is unknown. Cana-
foglia et al. described a single case of late-infantile NP-C
with severely disabling cortical myoclonus at the age of
eight years. They concluded that high-frequency myoclonus
may be subtle and easily overlooked at disease onset, poten-
tially leading to considerable delays in diagnosis [9]. Based
on our clinical experience in other patients with neuroge-
netic disorders with multiple movement disorders, [10]
myoclonus can be difficult to identify indeed, especially
when ataxia is present in the same patient. For this reason
we suspect that myoclonus is under-recognized in NP-C.
Psychiatric disorders and cognitive deficits are com-
mon in adults with NP-C and can precede the motor
symptoms [5]. Psychosis is one of the characteristic dis-
orders in the adult onset form of NP-C, but patients can
present with a variety of unspecific psychiatric problems.
Hence, the diagnosis is often delayed [11] and treatment
[12] can be delayed for several years. Vanier et al. de-
scribed depression and behavioral problems with aggres-
sion and withdrawal as possible psychiatric symptoms
that precede the motor signs of NP-C [1]. The number
of studies on cognitive functioning of patients with NP-
C is limited, but the existing studies show deficits in lan-
guage, information processing speed and divided atten-
tion, memory, visuospatial skills and constructional
praxis [13, 14]. Deficits in social cognition and other do-
mains contribute to the observed cognitive decline that
can be one of the precursors of NP-C [8].
In this paper we present eight Dutch cases of NP-C.
Early symptoms of NP-C include movement disorders,
psychiatric symptoms and cognitive deficits. For this rea-
son we investigated neuropsychological functioning in
seven patients with NP-C. We aim to increase know-
ledge of movement disorders and neuropsychiatric func-
tioning in NP-C. The goal of our study was to determine
the frequency of myoclonus in NP-C patients and to de-
termine the anatomical origin of the myoclonus. We
considered that recognition of myoclonus might be an
important diagnostic sign for NP-C and enables symp-
tomatic treatment to improve overall functioning [10].
Methods
We assessed the type and severity of neurological symp-
toms/movement disorders, behavioral and cognitive defi-
cits, health related quality of life (HRQoL) and daily
functioning in patients with NP-C. Inclusion criteria
were a confirmed molecular diagnosis of NP-C and age
at examination above 18 years. Twelve patients fulfilling
the inclusion criteria were found. Two patients passed
away during recruitment, two patients did not consent
to participate for various reasons, such as end stage dis-
ease. Finally, eight patients were included from two
Dutch University Medical Centers (University Medical
Center Groningen and Academic Medical Center
Amsterdam). This study was approved by the medical
ethical committee of the University Medical Center Gro-
ningen (METc2013.417). Data on demographics, age of
diagnosis, symptoms at onset, disease characteristics and
treatment were collected. To determine the presence
and severity of a movement disorder, all patients under-
went a standardized videotaped neurological examin-
ation. These videos were scored by an expert panel
through consensus discussions and by using the Global
Clinical Impressions Scale (GCI) [15]. In those patients
who were able to complete the tests and questionnaires,
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extensive neuropsychological testing was performed. The
assessment took place varying from directly after the diag-
nosis to 4 years after diagnosis. The neuropsychological
assessment covered emotion recognition as part of social
cognition, [16] but also intelligence, [17–19] working
memory, [20] verbal memory, [21] attention, [22] and
verbal fluency [19]. Results of the neuropsychological as-
sessment were compared to normative data as mentioned
in the test manuals. HRQoL and daily functioning were
examined using questionnaires (36-Item short form health
survey (Rand-36), Dutch Health Assessment Question-
naire (HAQ) and Sickness Impact Profile 68 (SIP-68)).
The scores on HRQoL and daily functioning in our cohort
were compared with published reference ranges for the
Dutch population [23, 24]. Also correlations between the
(non-) motor symptoms and QoL and daily functioning
were studied.
If patients were found to have myoclonic jerks at neuro-
logical examination, additional neurophysiological tests
were performed to analyze the relationship between myo-
clonus and cortical events. These tests consisted of simul-
taneous EEG and polymyography. Cortical activities were
recorded by standard EEG according to the international
10–20 system. Muscle activity was measured by nine
channel surface EMG with the electrodes placed on exten-
sor and flexor muscles of both upper and forearms, and
on the abductor pollicis brevis muscle on one side. A
standard myoclonus protocol was performed, assessing
rest periods, several postures and also the effect of several
stimuli, such as auditory, tactile and lightflash stimuli.
Back-averaging and coherence analysis were performed to
relate the cortical signals to EMG burst.
Results
Eight patients with a confirmed diagnosis of Niemann-
Pick type C were included. Their ages ranged from 19 to
61 years. Five patients presented with juvenile onset NP-
C and three patients with adolescent/adult onset NP-C.
All patients had mutations in the NP-C 1 gene. In seven
patients the mutations were detected through direct
Sanger sequencing of the NP-C genes and in one patient
(nr. 3) the diagnosis was made through a gene panel
with 88 genes related to movement disorders. In six pa-
tients Filipin staining was performed. In patient 1, 4, 5,
6, 7 and 8 Filipin stain was positive. No Filipin stain was
performed in patient 2 and 3.
The characteristics of the patients are shown in Table 1.
Three patients (nr. 2, 4, 8) had a history of prolonged
neonatal jaundice. Two other patients (nr. 5, 6) pre-
sented with visceral signs later in childhood including
(hepato) splenomegaly. In patient number 8 jaundice
and hepatosplenomegaly were reason for additional in-
vestigations which led to the diagnosis of NP- C before
any other symptom did occur.
In five out of eight patients non-specific changes were
seen on brain MRI, including white matter changes and/
or global (including cerebellar) atrophy.
Presenting neurological symptoms and current
neurological abnormalities
In retrospect, when asked patients or parents, involun-
tary movements were the first noticed neurological
symptom in six patients. Three presented with jerks very
suggestive of myoclonus (age 20, 25, 61) and three with
signs of ataxia (age 19, 26, 58). Psychosis was presenting
symptom in two patients, but neurological examination
revealed a movement disorder as well in both patients at
the initial presentation. In patient number 1 there were
signs of gait ataxia and VSGP (vertical supranuclear gaze
palsy), in patient number 5 dystonia of the right arm
and VSGP were present.
Table 1 Patient characteristics







1 Female Compound heterozygous mutations c.1211G > A
(p. Arg404Gln) and c.2861C > T (p. Ser954Leu)
18 23 35 No
2 Female Homozygous mutations c.3182 T > C (p.IIe1061Thr) 8 21 25 Yes
3 Male Compound heterozygous mutations c.2474A > G
(p.Tyr825Cys) and c.3019C > G (p.Pro1007Ala)
52 59 61 Yes
4 Female Homozygous mutations p.Gly640Arg 14 18 20 Yes
5 Male Compound heterozygous mutations c.346C > T
(p.R116X) and c.247A > G (p. Y825C)
14 17 19 No
6 Male Compound heterozygous mutations c.1918G > A
(p.Gly640Arg) and c.3451G > A (p.Ala1151Thr)
6 14 19 Yes
7 Male Compound heterozygous mutations c.3203C > T
(p.Thr1068IIe) and c.3614C > A (p.Thr1205Lys)
40 52 58 Yes
8 Female Homozygous mutations c.3182 T > C
(p.IIe1061Thr)
11 6 26 No
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In half of the patients signs suggestive of VSGP (im-
paired downward gaze manifesting itself with troubles
playing piano or working on the computer) and cogni-
tive problems were mentioned also early in disease by
patients or parents. However, unlike movement disor-
ders or psychosis, none of the patients sought medical
attention for this (Table 2).
In all patients the presenting movement disorder was
currently also the predominant movement disorder seen.
However, seven patients developed additional movement
disorders. Four of them had one additional movement
disorder and the other three patients two. This showed
that the majority of patients had mixed and sometimes
complex movement disorder phenotypes.
Upon current neurological examination, myoclonic
jerks were found to be present in five patients. In one
patient (nr. 3) the jerks were generalized and present in
all extremities, trunk, face and tongue. In the other four
patients, myoclonus was predominantly located distally
in the limbs and aggravated with posture maintenance
and active movements. The upper extremities were usu-
ally more affected than the lower extremities. In one of
these patients (nr. 4) there were perioral myoclonic jerks
as well. In all patients but one (nr. 3) myoclonus was
stimulus-sensitive. Negative myoclonus was seen in all
patients. On the GCI the myoclonus was considered to
be significant in two patients (4 and 5 on the scale of 7).
Myoclonus was however not the most frequently ob-
served movement disorder. Seven patients developed
ataxia of the extremities in the course of the disease, in-
cluding three patients who presented with myoclonus
(nr. 2, 3, 4).
Dystonia was also present in five patients, with only in
one of them dystonia being the presenting symptom. In
two patients generalized dystonia was observed; one
patient (nr. 1) suffered from dystonia of face, trunk and
extremities and in another patient (nr. 4) facial and cer-
vical dystonia were present combined with dystonic pos-
turing of the feet. In the other three patients dystonia
was more confined to the neck and shoulder region. Pa-
tient 5 showed minimal dystonia of the right arm and pa-
tient 6 had a combination of cervical and upper extremity
dystonia. Finally, patient 7 had severe cervical dystonia
with also dystonic postures of the left hand while writing.
One patient showed a tic of the head. Tremor, chorea
and parkinsonism were not observed in our cohort.
Myoclonus and electrophysiological characteristics
In four out of five patients (nr. 2, 3, 4, 7) with myoclo-
nus, EEG-EMG polygraphic study was performed. Pa-
tients were subjected to a standard myoclonus protocol.
Table 3 shows the results of the neurophysiological ana-
lysis of the four tested patients.
In all patients typical features of cortical myoclonus
were found with short EMG burst duration, both nega-
tive and positive myoclonus types, and with a predomin-
antly distal distribution. Activation of the myoclonus
was induced by posture. A detailed description of patient
2 is seen in Fig 1.
Cognitive dysfunction and psychiatric symptoms
Neuropsychological tests of five patients were available,
in two patients new assessments were performed. In one
patient no assessment was available. Not all patients
have completed the same tests. Estimations of
intelligence ranged from low average to average. Emo-
tion recognition as a basic aspect of social cognition was
compromised in the three assessed patients. Further-
more, patients showed impairments of working memory,
attention, verbal fluency and learning of verbal informa-
tion. Retention in long-term memory in relation to the
imprinting was average to above average in three of our
patients (Table 4).
Patients indicated elevated scores on the subscale som-
atic complaints of the Adult Self Report (ASR). Further-
more, patients and caregivers indicated elevated scores
on the subscale attention problems. However, all scores
were within the normal range and Wilcoxon signed rank
Table 2 Presenting and current movement disorders
Patient Presenting movement
disorder
Severity of current movement disorder (GCI) a
Ataxia Myoclonus Dystonia Tic Overall severity
1 Ataxia 5 1 3 1 5
2 Myoclonus 3 4 1 1 4
3 Myoclonus 2 3 1 1 3
4 Myoclonus 4 5 3 1 5
5 Dystonia 1 1 2 1 2
6 Ataxia 4 1 4 1 4
7 Ataxia 5 4 3 1 5
8 Ataxia 4 2 1 2 4
a GCI Global Clinical Impressions Scale, 1 (no movement disorder) - 7 (among the most extremely affected patients)
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tests showed no significant differences between patient
and caregiver.
Three patients were affected by a psychotic disorder
(nr. 1, 5, 8), one of them (nr. 1) was using antipsychotic
medication during this study. Neuropsychological data
were only available for two of these patients. Their
scores were average compared to the other patients in
the cohort.
Quality of life and daily functioning
The health related quality of life in our cohort, measured
with the RAND-36, was on several domains significantly
lowered compared to the general population [24]. Espe-
cially the general health perception was scored remark-
ably low, 35.0 on a scale of 0–100. Other domains that
were rated low were physical functioning, role limita-
tions due to physical problems and vitality, while the
Table 3 Electrophysiological characteristics
Patient Duration Frequency Location Type Back-averaging Coherence Reflex myoclonus
2 40–60 ms 0.1-10Hz Distal Positive and negative Positive Positive No
3 50–100 ms 0.1-10Hz Distal Positive and negative Positive Positive No
4 40–70 ms 0.1-10Hz Distal Positive and negative NAa Positive No
7 <70 ms 0.1-10Hz Proximal and distal Positive and negative NAa Positive No
a NA not applicable
Fig. 1 Electrophysiological characteristics of patient number 2. Left Panel: 6 s of raw EEG data with four left sided EMG channels, 2 and 3 are
biceps and triceps, 4 and 5 are wrist flexor and extensor muscles. EEG montage: average reference. Note the multiple small myoclonic discharges,
mostly in distal muscles, with small EMG burst duration and synchronous activation of agonists and antagonists. Background EEG pattern is
normal without signs of epileptiform activity. Right Panel: coherence analysis (upper panels) shows significantly increased coherence from 14 to
28Hz, with also increased coherence around the myoclonus discharge frequency (around 4Hz). The red line is the threshold for significant
coherence. The phase plot shows a linear decrease in phase from 14-28Hz (EEG leads EMG), with a calculated corticomuscular conduction time
of 20,7 ms. The analysis is based on a segment of 180 s with frequently occurring myoclonus during rest. The lower panels show the result of
back-averaging on the same segment. The average was based on 242 segments, with 75 ms pre-EMG onset and 25 ms post-EMG onset depicted.
In the mapping view (view from above) a clear positive-negative potential field can be seen in the right centroparietal area. The positive peak is
maximal at 23 ms before myoclonus onset
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domains social functioning, mental health and pain were
on average relatively spared (Table 5).
The level of functional disability in daily life, expressed
by the functional disability index (FDI, range 0–3), in
our patients was 1.56 (SD 1.02). This is considerably
higher than reference values of the general population,
where mean values of 0.03 to 0.05 are reported [23]
(Mann-Whitney U test: p = 0.001), indicating more func-
tional disabilities in our cohort.
It appeared that patients with a more severe movement
disorder as measured with the GCI Scale had a signifi-
cantly higher FDI (Spearman’s Rho: rs = 0.814, p = 0.014).
Also with another measure of impact on daily life,
the SIP-68, a significant relation was found between
the severity of the movement disorder and somatic
autonomy (Spearman’s Rho: rs = 0.706, p = 0.050) and
physiological autonomy/communication (Spearman’s
Rho: r =0.727, p = 0.041).
The RAND-36 domain concerning physical function-
ing was correlated with the severity of the movement
disorder; patients with more severe movement disorders
experienced more physical disabilities (Spearman’s Rho:
rs = −0.845, p = 0.008). No significant relation was shown
for the other QoL domains including emotional func-
tioning and well-being, energy, social functioning, pain,
general health and health change.
Discussion
We systematically assessed the presenting and current
symptoms in NP-C, with a special focus on move-
ment disorders and neuropsychiatric functioning. Not
unexpectedly, the most common movement disorder
was ataxia, but myoclonus was seen in five out of
eight patients. Furthermore dystonia was frequently
seen and one patient showed a tic. Neurological signs
are very common in NP-C and movement disorders
represent an important part of the neurological
phenotype. Although the presence of movement dis-
orders was not an inclusion criterion, all included pa-
tients in our cohort were routinely seen by a
neurologist, implicating a potential selection bias.
However, according to the literature only a minority
(13 %) of the patients with NP-C do not display any
neurological manifestations at all and most of these
patients have the infantile form of NP-C [2].
In all our patients movement disorders were a present-
ing neurological feature, often in combination with
VSGP, psychosis or cognitive deficits. Movement disor-
ders and psychosis were reason to seek medical atten-
tion; VSGP and cognitive decline were not. However,
also in patients with movement disorders help-seeking
delay was found, although the exact time span in our co-
hort is not known. Reason for this is that only the mo-
ment of first symptoms and final diagnosis were
reported in the medical history, data about previous
visits to general practitioners and other hospitals before
referral to an Academic Center were not available.
Incidence of ataxia as first presenting symptom in litera-
ture is 20 %, other movement disorders cover 11 % [5].
Table 4 Results of neuropsychological assessment per domain
Domain % Patients in 1st–5th percentile % Patients in 6th percentile or above Number of patients
Emotion recognitiona Total score 100 0 3
% Patients in 1st–9th percentile % Patients in 10th–49th percentile % Patients in 50th percentile
or above
Intelligenceb 29 43 28 7
Working memoryc 57 43 0 7
Verbal learningd 86 14 0 7
Retentiond 29 29 42 7
Attentione 80 20 0 5
Verbal fluencyf 100 0 0 5
aTest used: FEEST, bTests used: WAIS-III, WAIS-IV, GIT-2, PPVT-III-NL, NART cTests used: WAIS-III digit span, WAIS-IV digit span, dTest used: RAVLT, eTest used:
Trailmaking Test, fTests used: Fluency GIT-2, verbal fluency
Table 5 Health related quality of life





Physical 43.1 (40.9) 81.9 (23.2) p = 0.007
Social 73.4 (33.0) 86.9 (20.5) p = 0.248
Role limitations
(physical)
43.8 (37.5) 79.4 (35.5) p = 0.008
Role limitations
(emotional)
70.8 (45.2) 84.1 (32.3) p = 0.406
Mental health 84.0 (10.5) 76.8 (18.4) p = 0.055
Vitality 55.0 (16.5) 67.4 (19.9) p = 0.035
Pain 93.1 (19.5) 79.5 (25.6) p = 0.051
General health 35.0 (17.9) 72.7 (22.7) p < 0.001
Health change 50.0 (29.9) 52.4 (19.4) p = 0.821
SD standard deviation
*Independent samples t-test for equality of means, significance level p < 0,05
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This is considerably lower than in our cohort. Reason
for this might be the higher age of onset of NP-C in
our study. Movement disorders and psychiatric symp-
toms are the most common presenting symptoms in
adolescence and adult NP-C [1]. A combination of two
or more movement disorders, in this age group present
in seven patients, should raise suspicion of NP-C, espe-
cially in combination with eye movement disorders or
cognitive deficits.
We found myoclonus in five out of eight patients, of
which in three of them it was the first presenting move-
ment disorder. The reported frequency of myoclonus in
NP-C in the literature is low, but our study suggests that
this may be higher than expected. It is not unlikely that
myoclonus in NP-C is not always recognized and we can
imagine that when myoclonus is more subtle and mul-
tiple movement disorders are present, this can be over-
looked. Especially in patients with other movement
disorders that may be more dominant, subtle jerks can
be easily missed [10]. Recognition of myoclonus is very
important. Firstly because having an extra movement
disorder can be an important clue for diagnosing NP-C.
Furthermore, myoclonic jerks can be very disabling and
symptomatic treatment is possible. EEG and polymyo-
graphy showed that the myoclonus in NP-C has a cor-
tical origin and that it consists of both positive and
negative myoclonus. Furthermore, both low frequency
and high frequency myoclonus were found. Previous re-
ports in two patients also detected a cortical myoclonus
[4, 9]. For the treatment of cortical myoclonus, levetirac-
etam or piracetam are considered drugs of first choice.
Alternatives are clonazepam and valproic acid [25, 26].
The patients in our cohort experienced significantly
more functional disabilities compared to healthy con-
trols and a significant relation was found between the
severity of the movement disorder and psychical disabil-
ities. Recognition and adequate treatment of myoclonus
are likely to positively influence daily functioning, but
further treatment studies are required to support this
hypothesis.
Except one, all patients showing myoclonus also had
cerebellar ataxia. Cortical myoclonus is thought to result
from increased excitability of the sensorimotor cortex
due to decreased inhibition through the cerebellar-
thalamic-cortical loop [27]. The combination of cortical
myoclonus and cerebella ataxia is also seen in disorders
with prominent Purkinje cell loss, for example celiac dis-
ease [28, 29]. In NP-C brains, ballooned neurons, axonal
abnormalities, neurodegeneration and astroglyosis have
been described. Especially Purkinje cells of the cerebel-
lum are vulnerable to early damage and cell loss begins
early in disease [30, 31]. Damage to Purkinje cells may
play a role in cortical myoclonus and ataxia in NP-C and
these pathological findings support the shared pathology
of cortical myoclonus and ataxia in our patients. With
loss of Purkinje cells being a prominent feature of NP-C
and not only playing a role in ataxia but in myoclonus
as well, this also suggest that incidence of myoclonus in
NP-C might be higher than currently estimated. The
clinical syndrome of myoclonus and ataxia in combin-
ation of relatively mild epilepsy and mental retardation
is called progressive myoclonus ataxia (PMA) or the
Ramsay Hunt syndrome, [32] and seems applicable in
many cases with NP-C.
Present in seven patients, ataxia was the most com-
mon movement disorder in our group and is under-
scoring previous reports [2, 8]. However, it is important
to mention that not in all NP-C patients ataxia was the
presenting movement disorder. In three patients ataxia
developed later during the course of the disease. Hence,
ataxia was not the most prominent movement disorder
in all patients. In three patients with ataxia, myoclonus
was more severe. So, ataxia is an important neuro-
logical hallmark of NP-C, but its absence does not ex-
clude NP-C.
Besides movement disorders, cognitive deficits and
psychiatric features are early symptoms of NP-C, espe-
cially in the adolescent and adult form [5]. Two patients
developed a psychosis early in disease and also cognitive
deficits were among the early symptoms. Patients in our
sample showed cognitive deficits in all domains investi-
gated, in particular in working and verbal memory and
attention. This confirms earlier findings by Klarner et al.
[16]. We focused on social cognition in three patients
and found deficits in emotion recognition. More studies
with bigger sample sizes are needed in order to clarify
whether these deficits in social cognition are typically for
NP-C and when they develop in the course of the dis-
ease. This might help in identifying patients with NP-C
presenting with cognitive problems early in the course
of the disease and discriminating them from patients
with other neuropsychiatric disorders.
Conclusion
We presented evidence that movement disorders, psy-
chiatric symptoms and cognitive deficits are important
features of NP-C. Cortical myoclonus was seen in more
than half of the patients. The role of myoclonus in NP-C
is not yet established, but our study suggests that inci-
dence may be higher than considered until now. Careful
examination is required to detect myoclonus and other
movement disorders as they sometimes require specific
treatment. Nowadays, diagnosing NP-C is still a chal-
lenge for physicians. In adolescent and adult patients
presenting with mostly psychiatric and neurological
signs, knowledge of the exact phenotype of these symp-
toms is very important in order to diminish diagnosis
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delay. Further research is needed to determine the exact
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